| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Quinidine HydroHClone monohydrate has an IC50 of 19.9±1.41 μM and a Hill slope of 1.15±0.15 (n=7), indicating that it inhibits WT mSlo3 (KCa5.1) channels. Similarly, quinidine hydrochloride monohydrate has a stronger inhibitory potency against F304Y mSlo3 (IC50 = 2.42±0.60 μM, n = 9, P<0.005; Hill slope = 0.98±0.12), but a lower inhibitory potency (IC50 = 38.4±6.77 μM, n = 5, P<0.001; Hill slope = 1.05±0.16) against R196Q mSlo3. There is a time dependence detected in the inhibition of F304Y mSlo3 by quinidine hydrochloride monohydrate [1].
|
|---|---|
| ln Vivo |
When comparing baseline to other time points or comparison experiments, the direct application of quinidine hydrochloride monohydrate to the sciatic nerve produced dose-related decreases in the amplitudes of the descending compound muscle action potential (CMAP) and ascending somatosensory evoked potential (SSEP). Left versus right contralateral limbs treated with glucose. When quinidine hydrochloride monohydrate was applied, the latency of the SSEP and CMAP potentials increased in comparison to the baseline and contralateral side [2].
|
| References |
[1]. Wrighton DC, et al. Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium. Br J Pharmacol. 2015 Sep;172(17):4355-63.
[2]. Cheng KI, et al. Application of quinidine on rat sciatic nerve decreases the amplitude and increases the latency of evoked responses. J Anesth. 2014 Aug;28(4):559-68 |
| Molecular Formula |
C20H24N2O2.HCL.H2O
|
|---|---|
| Molecular Weight |
378.89298
|
| CAS # |
6151-40-2
|
| Related CAS # |
Quinidine (15% dihydroquinidine);56-54-2;Quinidine sulfate;50-54-4;Quinidine sulfate dihydrate;6591-63-5;Quinidine polygalacturonate;27555-34-6;Quinidine gluconic acid;7054-25-3
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C=C[C@H]1C[N@](CC[C@H]1C2)[C@@]2([H])[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34.[H]Cl.[H]O[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~263.93 mM)
H2O : ~2.5 mg/mL (~6.60 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6393 mL | 13.1964 mL | 26.3929 mL | |
| 5 mM | 0.5279 mL | 2.6393 mL | 5.2786 mL | |
| 10 mM | 0.2639 mL | 1.3196 mL | 2.6393 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
